AbbVie gains option to Teneobio BCMA program

AbbVie Inc. (NYSE:ABBV) will pay $90 million up front for an option to acquire bispecific antibody TNB-383B from Teneobio Inc. (Menlo

Read the full 216 word article

How to gain access

Continue reading with a
two-week free trial.